234
Participants
Start Date
April 30, 2005
Primary Completion Date
November 30, 2008
Study Completion Date
December 31, 2008
bapineuzumab
IV, Q13w
placebo
IV Q13w
Sergievsky Center, Columbia University, New York
University of Rochester / Monroe Community Hospital, Rochester
University of Pittsburgh, Pittsburgh
Georgetown University Medical Center, Washington D.C.
Department of Psychiatry and Behavioral Sciences, Durham
Mayo Clinic - Department of Neurology, Jacksonville
Brain Matters Research, Inc., Delray Beach
Department of Neurology - Indiana University Medical Center, Indianapolis
University of Michigan Health System, Department of Neurology, Ann Arbor
Mayo Clinic Department of Neurology - Alzheimer's Disease Research Center, Rochester
Rush Presbyterian St. Luke's Medical Center, Chicago
University of Texas Southwestern Medical Center, Dallas
Baylor College of Medicine, Houston
Cleo Roberts Center for Clinical Research / Sun Health Research Institute, Sun City
Pharmacology Research Institute, Los Alamitos
Pharmacology Research Institute, Northridge
UC Irvine, Irvine
Oregon Health and Science University, Portland
University of Washington, Seattle
UCSD Shiley-Marcos Alzheimer's Disease Research Center, San Diego
Memory & Aging Center, UCSF, San Francisco
Yale University School of Medicine, New Haven
Behavioral Neurology, Boston
The Memory Enhancement Center, Long Branch
Memory and Aging Program, Butler Hospital, Providence
Clinical Neuroscience Research Associates, Inc., Bennington
Collaborators (1)
Pfizer
INDUSTRY
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
INDUSTRY